Investigations revealed leucocytosis of 18,800/mm with 90% neutrophills. Blood Urea was 104 mg/dl and Serum creatinine 2.2 mg/dl. Liver Function Tests revealed raised AST and ALT of 117 mg/dl and 155 mg/dl respectively with low albumin levels of 2.3 mg/dl. Urine examination was normal.
OHSS is an iatrogenic complication of the luteal phase and/or early pregnancy after ovulation induction (provoking ovulation in anovulatory women) or of ovarian stimulation (in the context of intrauterine insemination or in vitro fertilisation). It ranges in severity from mild self limiting illness to a potentially fatal one. The pathophysiological hallmarks of the syndrome are cystic enlargement of the ovaries and abnormal capillary permeability resulting in third space fluid loss. Treatment is largely supportive with emphasis on adequate fluid resuscitation. Though Early OHSS is usually mild we report a case of 25 year old Female who developed Severe OHSS within one week of ovulation induction while undergoing In-vitro fertilization (IVF) with Embryo Transfer on account of oligospermia in her husband.
Material and Methods
A 25 years old Female with insignificant medical history in the past underwent IVF with Embryo Transfer after her husband was found to have Oligospermia. Patient initially received Gonadotropin Releasing Hormone (GnRH) analogue for downregulation of Pituitary function followed by Recombinant Follicle Stimulation Syndrome (rFSH) for ovarian stimulation that was followed by Human Chorionic Gonadotropin (HCG) for ovulation induction. Six days after receiving HCG patient developed abdominal discomfort and distention. One day later patient developed breathlessness and had decreased urine output and was admitted in our hospital. Treatment of OHSS is largely supportive. Medical management is mainly to maintain circulatory function and prevent organ dysfunction. The intravascular volume should be maintained to prevent hemoconcentration and allow sufficient 3 urine output. Initial fluid of choice is crystalloids. Intravascular volume expansion with dextran has been associated with 13 development of ARDS in patients with OHSS. In patients with hematocrit more than 45% or hypoalbuminemia less than 30gm/L or ascites, human albumin is the plasma expander of choice. In severe cases of OHSS prophylactic anticoagulation should be used. In presence of thromboembolism therapeutic 3, 5 anticoagulation is indicated.
Conclusion
OHSS can be a severe complication of infertility treatment and fatalities have been reported. The affected patients are usually young females who otherwise have no significant illness and hence it is important for healthcare providers to be aware of its clinical features, complications and management to prevent its disastrous outcome. Management is largely supportive with emphasis on adequate fluid resuscitation and prevention of complications especially venous and arterial thrombosis.
